Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Lilly Licenses Deciphera Technology ...
by Lisa M. Jarvis
October 13, 2008
| A version of this story appeared in
Volume 86, Issue 41
Eli Lilly & Co. has teamed with Lawrence, Kan.-based Deciphera Pharmaceuticals to discover and develop drugs that block B-Raf kinase, a protein commonly mutated in cancer. Deciphera will be tasked with discovering small molecules that target the "switch pocket," a region on the protein that controls its shape and activity. The pact covers four projects related to selective or multikinase inhibitors, with Lilly retaining the exclusive rights to any product developed. Deciphera gains an up-front payment, two years of research funding, and possibly $130 million per compound developed.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X